|S2196||Dabigatran (BIBR 953)||<1 mg/mL||0.5 mg/mL||0.01 mg/mL|
|S2229||Eltrombopag Olamine||<1 mg/mL||89 mg/mL||<1 mg/mL|
|S2154||Dabigatran Etexilate||<1 mg/mL||126 mg/mL||12 mg/mL|
|S1346||Heparin sodium||100 mg/mL||<1 mg/mL||<1 mg/mL|
|S2069||Argatroban||<1 mg/mL||9 mg/mL||6 mg/mL|
|S5286||Ramatroban||<1 mg/mL||83 mg/mL||83 mg/mL|
|S5252||Ozagrel sodium||50 mg/mL||1 mg/mL||<1 mg/mL|
|S5074||Argatroban hydrate|Argipidine||<1 mg/mL||100 mg/mL||40 mg/mL|
|S3200||Triflusal||<1 mg/mL||50 mg/mL||50 mg/mL|
|S4740||Sodium ferulate||43 mg/mL||2 mg/mL||<1 mg/mL|
|S4502||Eltrombopag||<1 mg/mL||26 mg/mL||<1 mg/mL|
Dabigatran (BIBR 953) is a potent nonpeptide thrombin inhibitor with an IC50 of 9.3 nM in a cell-free assay.
The peak fluorescence of each time course at the specified drug concentration are plotted as a function of concentration of (C) dabigatran. Each dose-response curve was fitted to the Hill equation, and these curves are shown in red for thrombin inhibitors (B,C).
Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).
Dabigatran Etexilate is the prodrug of dabigatran, a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.
Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins, used as an anticoagulant.
Argatroban is a potent and selective synthetic thrombin inhibitor with Ki ranging from 5 nM to 39 nM, used as an anticoagulant.
Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.
Sodium ferulate (SF), the sodium salt of ferulic acid, is a drug used in traditional Chinese medicine for treatment of cardiovascular and cerebrovascular diseases and to prevent thrombosis.
Eltrombopag, a member of the biarylhydrazone class, is a nonpeptide agonist of the thrombopoietin receptor (TpoR), used to treat chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).
Effect of eltrombopag on cell cycle progression in Huh7 cells. (A) Cells were treated with EP (0 and 10 μg/ml) for 72 h. DNA was stained with propidium iodide, and flow cytometric analysis of cell phase distribution was performed using a Muse™ cell analyzer. (B) Cells were treated with EP (0, 1 and 10 μg/ml) for 72 h. Protein expression was determined by western blot analysis using anti-cyclin D1, anti-p21 and anti-GAPDH antibodies. SDS-PAGE was performed on acrylamide gels.